AVANIR Pharmaceuticals (AVANIR) is a pharmaceutical company focused on developing, acquiring and commercializing therapeutic products for the treatment of chronic diseases. The Company's product candidates address therapeutic markets that include the central nervous system, inflammatory diseases and infectious diseases. Its principal product candidate, Zenviatm (dextromethorphan hydrobromide/quinidine sulfate), is in Phase III clinical development for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain). AVANIR's first commercialized product, docosanol 10% cream, (sold as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare in North America) is an over-the-counter treatment for cold sores that has been approved by the United States Food and Drug Administration (FDA). AVANIR entered into an agreement in July 2007, to sell FazaClo to Azur Pharma, Inc. (Azur). The sale was closed on August 3, 2007.
(Source: 10-K)
AVANIR Pharmaceuticals (AVANIR) is a pharmaceutical company focused on developing, acquiring and commercializing therapeutic products for the treatment of chronic diseases. The Company's product candidates address therapeutic markets that include the central nervous system, inflammatory diseases and infectious diseases. Its principal product candidate, Zenviatm (dextromethorphan hydrobromide/quinidine sulfate), is in Phase III clinical development for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain). AVANIR's first commercialized product, docosanol
...
Scholarships
There are no scholarships at this time
Events
There are no events at this time
Company Data on
Avanir Pharmaceuticals, Inc
provided by
Avanir Pharmaceuticals, Inc is hiring for these positions